Phase 2
N=5
Hidradenitis Suppurativa Wound Care
Hidradenitis Suppurativa (HS)
Bottom Line
View on ClinicalTrials.gov: NCT04354012 ↗Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcome: Primary: Percent Change in Wound Size — 57.2 percentage change in wound size
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- methylene blue, gentian violet, and ovine forestomach wound dressings (Combination_product)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Wake Forest University Health Sciences
- Primary completion
- Aug 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change in Wound Size |
57.2 | — |
| SECONDARY Change in Pain Assessment Scores |
3.12 | — |
| SECONDARY Change in Pain Assessment Scores |
3.12 | — |
| SECONDARY Change in Pain Assessment Scores |
3.12 | — |
| SECONDARY Change in Pain Assessment Scores |
3.12 | — |
Summary
The objective of this case series is to monitor time and outcome of healing of wounds associated with HS using Endoform [ovine forestomach], Hydrofera Blue [methylene blue and gentian violet], and Hypafix tape. a combination methylene blue, gentian violet, and ovine forestomach wound care product.
Eligibility Criteria
Inclusion Criteria
- Individuals with hidradenitis suppurativa with non-healing wounds or draining abscesses/nodules
- Individuals over 18 years of age
Exclusion Criteria
- Individuals younger than 18 years of age
- Individuals without a diagnosis of HS
Data sourced from ClinicalTrials.gov (NCT04354012). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.